Mapping the developmental path for Parkinson’s disease therapeutics

The National Institute of Neurological Disorders and Stroke (NINDS) held an open workshop on April 23 and 24, 2024 to evaluate the gap between the current understanding of Parkinson’s disease (PD) and the development of therapeutics for treating PD. Representatives from key stakeholder groups discussed strategies for leveraging research to bridge this gap. Sessions focused on PD heterogeneity, target validation, development of tools and resources to facilitate therapeutics development, biomarker discovery and use, similarities and differences with PD-adjacent neurodegenerative diseases, and best practices for accelerating the therapeutics development process. Here are some of the main takeaways from the workshop.

Authors

Institutions

Publication Details

Journal
npj Parkinson s Disease
Published
2025-11-07
DOI
https://doi.org/10.1038/s41531-025-01154-1
Primary Topic
Parkinson's Disease Mechanisms and Treatments
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Mapping the developmental path for Parkinson’s disease therapeutics

Hyun Joo Cho, Beth-Anne Sieber, Lauren A. Laboissonniere, Amir P. Tamiz et al.
npj Parkinson s Disease
Parkinson's Disease Mechanisms and Treatments
article

Mapping the developmental path for Parkinson’s disease therapeutics

Hyun Joo Cho, Beth-Anne Sieber, Lauren A. Laboissonniere, Amir P. Tamiz, Rebecca B. Price, Lyn B. Jakeman, Shireen A. Sarraf, William J. Martin, Carl Wonders, Alice Chen‐Plotkin, Christine L. Torborg, Christine Swanson‐Fischer, Rebekah Corlew, Neel T. Dhruv, Sarah Robinson Schwartz
article en

Abstract

The National Institute of Neurological Disorders and Stroke (NINDS) held an open workshop on April 23 and 24, 2024 to evaluate the gap between the current understanding of Parkinson’s disease (PD) and the development of therapeutics for treating PD. Representatives from key stakeholder groups discussed strategies for leveraging research to bridge this gap. Sessions focused on PD heterogeneity, target validation, development of tools and resources to facilitate therapeutics development, biomarker discovery and use, similarities and differences with PD-adjacent neurodegenerative diseases, and best practices for accelerating the therapeutics development process. Here are some of the main takeaways from the workshop.

npj Parkinson s DiseaseVol. 11(1)
Johnson & Johnson (United States) (US), National Institute of Neurological Disorders and Stroke (US), University of Pennsylvania (US)
Australian Government, National Institutes of Health, National Institute of Neurological Disorders and Stroke
Openalex Percentile: Top 54%
Parkinson's Disease Mechanisms and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.